M Ventures

What M Ventures does

M Ventures is the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany, established in 2009 and headquartered in Amsterdam, with additional offices in the United States and Israel. The firm invests across two principal verticals, Biotechnology (Healthcare drug development, Life Science tools) and Technology (Electronics, Frontier Technology & Sustainability), executing a dual strategic and financial mandate: deploying Merck KGaA capital into visionary early-stage companies whose scientific or technological progress can feed back into Merck KGaA's core businesses while generating financial returns.

The firm operates with a €600 million fund allocation, established through a December 2021 commitment by its parent, and has executed over 100 investments since inception. Investment activity spans seed through Series D financings and includes both lead positions and co-investment roles alongside tier-one sponsors such as Pfizer Ventures, Taiho Ventures, ARCH Venture Partners, Koch Disruptive Technologies, and SV Health Investors. Recent activity (late 2024 through mid-2026) shows accelerating cadence and thematic diversification into AI infrastructure adjacencies (optical interconnects, Edge AI processors, AI-data-center thermal management) alongside established oncology, immunology, and CNS therapeutics franchises.

The business model is investment-driven: M Ventures earns management fees on its parent-committed capital and realizes returns through equity stakes, which it may exit via strategic acquisition (e.g., Calypso Biotech acquired by Novartis in January 2024) or follow-on financing events. Portfolio value-add beyond capital includes access to Merck KGaA's scientific, regulatory, and commercial networks, founder-friendly engagement, and active board involvement. The firm employs 11–50 staff and is managed by a team that includes Managing Directors Hakan Goker (biotechnology) and Roel Bulthuis (digital medicine), with functional leads across healthcare, life sciences, Israel operations, and legal strategy.

Name

M Ventures

Legal name

M Ventures

Website

https://m-ventures.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

M Ventures is the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany, investing since 2009 from Amsterdam across Biotechnology and Technology with a €600M fund allocation, supporting early-stage portfolio companies through capital and access to Merck's scientific and commercial networks.

Ownership category

akta.pro rank

Product category

Corporate Venture Capital

NAICS

All Other Financial Investment Activities (52399), Miscellaneous Financial Investment Activities (523999)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

akta.pro secondary industries

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD), Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Corporate venture capital
• Biotech venture investing
• Deep tech investments
• Early-stage life sciences
• Strategic CVC fund

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Portfolio Returns and Equity Stakes: M Ventures generates returns through equity stakes in portfolio companies. As a CVC arm of Merck KGaA, investments are made with dual strategic and financial foci, seeking transformational ideas that align with Merck KGaA's core business areas while generating financial returns through successful exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

M Ventures is the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany, investing in early-stage visionary companies across Biotechnology and Technology sectors. It deploys approximately €600 million in capital into portfolio companies spanning healthcare drug development, life science tools, electronics, and frontier technology & sustainability. M Ventures takes an active role in portfolio companies and teams up with entrepreneurs and co-investors to translate innovation toward commercial success, leveraging dual strategic and financial investment criteria.

Product overview

M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany. It is not a product company but rather an investment firm that deploys capital across two main sectors: Biotechnology (targeting challenging diseases and disruptive R&D/manufacturing tools) and Technology (computing, data storage, display, and sustainability solutions). The organization manages approximately €600m in fund allocation, has made over 100 investments since inception in 2009, and takes an active role in supporting portfolio companies. M Ventures does not offer products or services in the traditional SaaS/product sense.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Over 100 investments made since 2009
• +1 more outcomes

Named customers16 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Hakan Goker (Managing Director)coreOthers · 9 January 2026Hakan Goker is the Managing Director at M Ventures, responsible for the biotechnology investment strategy. He discussed the organization's role in driving innovation within pharmaceutical and biotechnology sectors with a vision for 2026.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Pfizer Ventures: Corporate venture capital arm of Pfizer, investing in early-stage biotech and healthcare companies. Direct peer to M Ventures with overlapping portfolio companies (STORM Therapeutics, FoRx Therapeutics, TRIMTECH) and repeated co-investment relationships.
• Novartis Venture Fund: Corporate venture capital arm of Novartis, focused on early-stage life science investments. Direct peer given similar pharma CVC structure, biotech focus, and demonstrated acquisition appetite for CVC-backed assets (e.g., Calypso Biotech acquired by Novartis).
• Roche Venture Fund: CVC arm of Roche investing in early-stage biotechnology and diagnostics. Comparable as a strategic pharma venture investor with similar early-stage biotech focus, deal sizes, and dual strategic/financial mandate.
• SR One (GSK): CVC arm of GSK investing across biotech, including therapeutics and platform technologies. Comparable structure as pharma CVC with similar early-stage focus and active co-investment profile.
• Boehringer Ingelheim Venture Fund: CVC of Boehringer Ingelheim investing in early-stage biotech and health tech, headquartered in Germany. Strong comparability as a strategic European pharma CVC with similar dual mandate and biotech focus.
• Sanofi Ventures: CVC arm of Sanofi focused on biotech and digital health. Direct peer as a strategic pharma CVC with comparable fund size, early-stage focus, and dual strategic/financial mandate.
• Amgen Ventures: CVC arm of Amgen investing in early- and growth-stage biotechnology. Comparable as a strategic pharma CVC with similar therapeutic focus and dual mandate approach.
• Bayer Leaps by Bayer: Investment arm of Bayer focused on breakthrough technologies in health and agriculture. Comparable as a large strategic pharma CVC with similar dual strategic and financial objectives and emphasis on transformational science.
• ARCH Venture Partners: Leading US-based early-stage biotech and deep tech VC. Comparable for its early-stage conviction investing model, repeat co-investment relationship with M Ventures (Lightcast, Nouscom, STORM), and similar concentration in transformative biotech and frontier tech.
• Koch Disruptive Technologies: Strategic investment arm of Koch Industries focused on transformative technology. Comparable for its deep tech and photonics/semiconductor focus, co-investment relationship with M Ventures (OFC 2026 event partnership, NovoLINC), and similar large-check strategic mandate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks4 records

Key highlights7 records

Customer concentration

• Xx.com/merckventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments180 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about M Ventures